AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed · Phase 2

Conditions studied: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor

In brief

This phase II trial is studying how well AZD2171 works in treating patients with recurrent glioblastoma multiforme. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Key facts

Study ID

NCT00305656

Run by

National Cancer Institute (NCI)

People needed

31

Starts

2006-01-01

Last updated by the study team

2013-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.